In addition, many other signatures were overexpressed in just CD8+ BRAF-CRCs and not in MSI BRAF-CRCs (Figure 2), including immune response profiles measuring lymphoid, macrophage, NK, CD45, and CD8 T cells abundance, interferon signaling response and Nitric Oxide Synthase 2 gene expression, exhausted CD8 cells and inhibitory tumor mechanisms that suppress anti-tumor immune activity including upregulation of PD-L2, PD-1, TIGIT, CTLA4. This evidence concerns the gene TIGIT and neoplasm.